{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:46:07Z","timestamp":1776329167636,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T00:00:00Z","timestamp":1285804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> Efficacy and safety of adjunctive rufinamide (3,200\u2003mg\/day) was assessed in adolescents and adults with inadequately controlled partial\u2010onset seizures receiving maintenance therapy with up to three antiepileptic drugs (AEDs).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group, multicenter study comprised a 56\u2010day baseline phase (BP), 12\u2010day titration phase, and 84\u2010day maintenance phase (MP). The primary efficacy variable was percentage change in total partial seizure frequency per 28\u2003days (MP vs. BP). Secondary efficacy outcome measures included \u226550% responder rate and reduction in mean total partial seizure frequency during the MP. Safety and tolerability evaluation included adverse events (AEs), physical and neurologic examinations, and laboratory values. Pharmacokinetic and pharmacodynamic assessments were conducted.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Three hundred fifty\u2010seven patients were randomized: 176 to rufinamide and 181 to placebo. Patients had a median of 13.3 seizures per 28\u2003days during BP; 86% were receiving \u22652 AEDs. For the intent\u2010to\u2010treat population, the median percentage reduction in total partial seizure frequency per 28\u2003days was 23.25 for rufinamide versus 9.80 for placebo (p<jats:italic>\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.007). Rufinamide\u2010treated patients were more than twice as likely to have had a \u226550% reduction in partial seizure frequency (32.5% vs. 14.3%; p<jats:italic>\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001) and had a greater reduction in median total partial seizure rate per 28\u2003days during the MP (13.2 vs. 5.2; p<jats:italic>\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). Treatment\u2010emergent AEs occurring at \u22655% higher incidence in the rufinamide group compared with placebo were dizziness, fatigue, nausea, somnolence, and diplopia.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Adjunctive treatment with rufinamide reduced total partial seizures in refractory patients. AEs reported were consistent with the known tolerability profile of rufinamide.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02729.x","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T21:31:32Z","timestamp":1285882292000},"page":"234-242","source":"Crossref","is-referenced-by-count":49,"title":["A randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study of rufinamide as adjunctive therapy for refractory partial\u2010onset seizures"],"prefix":"10.1111","volume":"52","author":[{"given":"Victor","family":"Biton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Vasquez\u2010Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bibbiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Narurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00589.x"},{"key":"e_1_2_7_3_1","volume-title":"[US product information]","author":"Banzel","year":"2008"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02160.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.12.003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.12.1931"},{"key":"e_1_2_7_7_1","volume-title":"[Summary of product characteristics]","author":"Inovelon","year":"2007"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00185-6"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70215-6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01665.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02729.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02729.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:43:04Z","timestamp":1697388184000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02729.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,30]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02729.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02729.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,30]]}}}